CD8

488,00 plus VAT

#DIA-TC8
Anti-CD8 (HU) aus Maus (Klon TC8) – 500 µl

Beschreibung

Prod.Nr. DIA-TC8
Spezifität CD8
Speziesreaktivität Human
Speziesreaktivität Mouse
Isotyp IgG2a k
Klon TC8
Anwendung
Immunohistochemistry (IHC),
Formalin-fixed Paraffin-embedded sections (FFPE)
Western Blot
Konjugation unconjugated
Verdünnung IHC 1:100-1:200
Format
Lyophilisate, 100µg
Antibody purified (from culture supernatant)
Anzahl 500µl
Positive control Tonsil
Format PBS pH 7.4, 2%BSA, 0.05%NaN3
Anwendungshinweis Research Use Only
Hersteller ONCOdianova
CD8 IHC-Gallery
IHC-figures and legends on CD8 detection in multiple tumors.

Reaktivität

Clone TC8 has been developed specifically for the immunohistochemical (IHC) detection of CD8 in routine FFPE human tissue specimen. TC8 has been validated for the identification of CD8 positive tumor infiltrating T cells (TILs) with the aim to allow an unequaled specific detection of CD8 in the tumor microenvironment. IHC application of monoclonal antibody TC8 may provide valuable information for clinical research and potential therapeutic interventions targeting the tumor immunology checkpoint.

IHC Protokoll

Staining protocols for anti-human CD8 antibody clone TC8
Cat.No.: DIA-TC8
Isotype: Mouse IgG2a/k
Specificity: Human CD8
Physical State: Lyophilized powder
Reconstitution: DIA-TC8, restore to 500µl. Reconstitute with sterile destilled water by gentle shaking for 10 minutes.
DAKO  – autostainer Link 48
  • Pretreatment buffer: 15 min. / 95°C / pH9
  • Incubation primary antibody: 20 min. / RT (Dilution: 1:200)
  • Link: no
  • HRP (polymer): 20 min. / RT
BOND – Leica Bond RX
  • Pretreatment buffer: 15 min / 100°C / pH9
  • Incubation primary antibody: 15 min (Dilution 1:200)
  • Post Primary: 8 min
  • HRP (Polymer): 8 min
Ventana – Discovery Ultra
  • Pretreatment buffer: 24 min / 100°C / pH9
  • Incubation primary antibody: 60 min / 38°C (Dilution 1:200)
  • Secondary antibody: 12 min / 36°C
  • HRP (polymer): 12 min
Manual stain with autoclave
  • Pretreatment buffer: 121°C / 5 min / pH7,8
  • Incubation primary antibody: 60 min / 37°C (Dilution: 1:200)
  •  Envision HRP rabbit/mouse: 30 min / 37°C
Manual stain with microwave
  • Pretreatment buffer: 90 sec, 1000 Watt to cooking, then 15 min / 270 Watt / pH7,8
  • Incubation primary antibody:  60 min / 37°C (Dilution: 1:100)
  • Envision HRP rabbit/mouse: 30 min / 37°C
2-colour immunoflorescence manual stain
  • Position 1: Antibody at pH9
  • Position 2: CD8
  • Pretreatment buffer: 90 sec, 1000 Watt to cooking, then 15 min / 270 Watt / pH9
  • Incubation primary antibody: 30 min / RT (Dilution 1:200)
  • HRP (Polymer): 10 min / RT

Referenzen

References

  1. Weynants P et al. Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. Am J Respir Crit Care Med (1999) 159(1):55–62.
  2. Echchakir H et al. Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int Immunol (2000) 12(4):537–46.
  3. Karanikas V et al. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res (2001) 61(9):3718–24.
  4. Piccirillo CA et al. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol (2001) 167(3):1137–40.
  5. Bossi G et al. The secretory synapse: the secrets of a serial killer. Immunol Rev (2002) 189:152–60.
  6. Pages F et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 353(25):2654–66.
  7. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother (2006) 29(3):233–40.
  8. Kvistborg P et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med (2014) (254):254ra128.
  9. Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 515(7528):568–71.
  10. Schumacher TN et al. Neoantigens in cancer immunotherapy. Science (2015) 348(6230):69–74.
Menü